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Abstract: Introduction: Endocrine disorders during Von Recklinghausen’s Disease or neurofibromatosis type 1 (NF1) are 
rare and particularly observed in children. However, autoimmune diabetes mellitus (DM) remains exceptional and 
unusual during this phacomatosis. We report an original case of Latent Autoimmune Diabetes in Adults (LADA) 
associated with NF1. 
Case Report: A 32-year-old Tunisian male, known to have NF1 since childhood, was admitted for significant recent 
weight loss (10 kg in one month) with high blood glucose levels. The biological tests confirmed the diagnosis of DM with 
marked ketoacidosis: fast blood glucose at 16 mmol/l, postprandial glucose at 21 mmol/l, and HbA1c at 9.9%. 
Radiological and endoscopic investigations did not indicate pancreatic and/or duodenal tumors. Anti-GAD and anti-IA2 
autoantibodies were positively confirming the diagnosis of LADA. The assessment of degenerative complications and 
screening for possible other autoimmune diseases were negative. The evolution was favorable under intensive 
insulinotherapy. 
Conclusion: The association of DM type 1 with NF1 remains exceptional and only four cases are found in the literature, 
all pediatrics. Our observation is, to our knowledge, the first reporting this association in adult (LADA with NF1). 
Keywords: Latent Autoimmune Diabetes in Adults, LADA, neurofibromatosis type 1, Von Recklinghausen’s 
Disease, diabetes mellitus. 
INTRODUCTION 
First described in 1882 by Von Recklinghausen, 
neurofibromatosis type 1 (NF1), also known as Von 
Recklinghausen's disease, is a rare phacomatosis: 
prevalence estimated at 1/3500 to 1/3000 live births, 
with autosomal dominant inheritance [1,2]. 
The mutation responsible for the disease affects the 
neurofibromatosis gene located on chromosome 17 
(17q11.2.) encoding neurofibromin, which 
physiologically regulates the proliferation and 
maturation of glial and neuronal cells [1-3]. 
The clinic is dominated by cutaneous signs (café au 
lait spots and freckling) and neurological signs 
(peripheral neurofibromas and gliomas). There are 
several other rarer manifestations (ocular, cardiac, 
vascular, bone, endocrine, etc.) marking the systemic 
nature of this disease and making it serious [1-3]. 
Diabetes mellitus (DM), however, remains an 
exceptional and unusual manifestation during this 
neurofibromatosis [4-6]. 
We are reporting an original observation of Latent 
Autoimmune Diabetes in Adults (LADA) associated 
with NF1. 
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CASE REPORT 
A 32-year-old Tunisian male, known to have NF1 
since childhood, was admitted for significant recent 
weight loss (10kg in one month) with high blood 
glucose levels in the emergency department. 
The diagnosis of NF1 was held in the presence of 
several café au lait spots (pigmented birthmarks), of 
different sizes and diffuse throughout the body 
(abdomen, thorax, face, and limbs) (Figures 1, 2, and 
3), freckling in the axillary and inguinal regions, bilateral 
Iris Lisch nodules, and multiple subcutaneous 
neurofibromas in the anterior chest wall, abdomen, 
back and four limbs (Figures 1, 2, and 3). During 
childhood, the investigations did not notice any central 
neurological, cardiac, bony, or intra-abdominal visceral 
involvement. 
The patient was afebrile; his haemodynamic state 
was preserved and had no cutaneous-mucous 
jaundice. He reported no diarrhea or abdominal pain. 
The biological tests confirmed the diagnosis of DM 
with marked ketoacidosis: FBG at 16 mmol/l, 
postprandial glucose at 21mmol/l and HbA1c at 9.9%. 
The other basic biological examinations were without 
abnormalities, in particular, the ionogram, creatinine, 
inflammatory, infectious, and liver tests. 
The patient was rapidly and intensively rehydrated 
with rapid continuous human insulin therapy until the 
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disappearance of ketone bodies and normalizations of 
blood glucose levels. 
 
Figure 1: multiple café au lait spots and subcutaneous 
neurofibromas in the anterior chest wall and abdomen. 
 
 
Figure 2: multiple café au lait spots and subcutaneous 
neurofibromas in the lower abdomen and the anterior faces of 
the arms. 
Radiological and endoscopic investigations did not 
indicate pancreatic and/or duodenal tumors (abdominal 
ultrasound, abdominal MRI, and gastroduodenal 
fibroscopy). 
In front of inaugural ketoacidosis, young age, and 
recent weight loss, the immunological nature of 
diabetes was suspected and confirmed by the positivity 
of anti-GAD (253 IU/ml, N<10 IU⁄ml) and anti-IA2 
autoantibodies (22 IU/ml, N<8 IU/ml). Thus the 
diagnosis of Latent Autoimmune Diabetes in Adults 
(LADA) associated with NF1 was retained. The 
assessment of degenerative complications and 
screening for possible other autoimmune diseases 
were negative. 
 
Figure 3: multiple café au lait spots and subcutaneous 
neurofibromas in the back. 
The patient was subsequently switched to fast-
acting and long-acting insulin analogues according to 
complete basal-bolus protocol with favorable evolution. 
DISCUSSION 
Endocrine disorders during NF1 are rare and are 
particularly observed in children. They may be of type: 
central precocious puberty, GH deficiency or on the 
contrary a GH hypersecretion, obesity with insulin 
resistance/glucose intolerance, ACTH deficiency, 
thyrotropin deficiency, and hypogonadotropic 
hypogonadism [1,7]. These manifestations are most 
often secondary to the presence of optic pathway 
gliomas invading or compressing the hypothalamus 
and sellar region [1,7]. 
These different endocrine disorders seem, however, 
to be very underestimated; in fact, in the series of Sani 
I and Albanese A, these disorders appeared in 55.6% 
of patients with NF1 during the course of the disease 
within an average of 2.4 years [7]. 
Among all endocrine disorders, DM remains 
exceptional and unusual during NF1 [4-6], and it is 
classic to say that the risk of diabetes during NF1 is low 
due to a state of insulin sensitivity significantly 
increased in subjects with this disease compared to the 
general population, even after adjusting for age, sex, 
and BMI [8]. 
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These findings were validated by several 
comparative studies and using several indices of 
insulin resistance and insulin sensitivity: FBG, 
postprandial glucose, HbA1c, HOMA-AD, HOMA-IR, 
ALR, liptin, visfatin,... [8], and in major national studies 
of morbidity and mortality [9-11]: Martins AS, showed 
that the risk of having a high FBG (defining diabetes 
mellitus) is 89% lower among subjects with NF1 
compared to the general population matched for age, 
sex, and BMI [12], and in the series of 8,579 subjects 
with NF1, Madubata C, noted a prevalence of DM of 
only 2.4% compared to a general prevalence in the 
population of 3.7%, (odds ratio of 0.4) [9]. 
The first description of the association of DM with 
NF1 dates back to 1941 by Halperan SR et al. [13] and 
since then only sporadic cases of DM have been 
reported in this disease. It is type 2 diabetes [10,11], 
type 1 diabetes [4,6,14,15] and secondary diabetes 
due to a somatostatinoma-type neuroendocrine tumor 
[5,16,17]. The exact frequency of glycemic 
abnormalities during NF1, however, seems to be very 
underestimated; they were noted in 11.1% of pediatric 
forms of the disease during prolonged follow-up [7]. 
The exact mechanism of DM during NF1 remains 
unclear and several hypotheses are discussed. 
Hyperglycemic states during NF1 may be secondary to 
hypersomatostatinemia, exerting an inhibitory effect on 
insulin secretion [5,17]. This hypersomatostatinemia is 
most often related to a pancreatic or duodenal 
somatostatinoma-type neuroendocrine tumor, which in 
the context of NF1 is part of “syndrome of multiple 
endocrine neoplasia” type III [5,18]. In these cases, 
glycemic abnormalities normalize after surgical 
excision of the tumor [17]. 
A second hypothesis less evoked is the protective 
role of mutated neurofibromin? Indeed, studies on the 
animal model have shown that physiological 
neurofibromin plays a role in regulating the functions of 
the hypothalamus and pituitary gland, which are 
involved in the global energy balance of the body 
[12,19 ]. 
Exceptionally, an immunological disorder may 
explain cases of type 1 DM, as well as the sporadic 
association of NF1 with other autoimmune diseases 
[4,6,15]. The review of the literature found only four 
cases of type 1 diabetes associated with NF1 
[4,6,14,15]. To the best of our knowledge, our 
observation is, the fifth case reporting with this 
association. It is characterized in addition by the late 
onset of diabetes in adulthood; the other observations 
already reported were all pediatric.  
CONCLUSION 
As rare as it may be, the association of DM with 
NF1 must be known by the clinician, given the 
particular prognostic and therapeutic implications, 
especially since diabetes may be the first manifestation 
of the disease. The causes of diabetes can be mainly a 
pancreatic or duodenal somatostatinoma that must be 
diagnosed and treated in time, more rarely a type 2 
diabetes in relation to endocrine abnormalities specific 
to NF1 (obesity/insulin resistance/glucose intolerance), 
and exceptionally type 1 autoimmune diabetes. Our 
observation is, to our knowledge, the fifth reporting the 
association of type 1 DM to NF1 and the first of LADA 
type DM. This association again raises the 
immunological disturbance suspected of NF1. 
ABBREVIATIONS 
ACTH = Adrenocorticotropic hormone 
Anti-GAD = Anti-glutamic acid decarboxylase 
antibodies 
Anti-IA2 = Anti-tyrosine phosphatase-related islet 
antigen 2 antibodies 
ALR = Adiponectin/leptin ratio 
BMI = Body mass index 
FBG = Fasting blood glucose 
GH = Growth hormone 
HbA1C = Glycated hemoglobin A1c 
HOMA-AD = Homeostasis model assessment 
adiponectin 
HOMA-IR = Homeostasis model assessment insulin 
resistance 
MRI = Magnetic resonance imaging 
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